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60Background: Vismodegib, a first-in-class Hedgehog pathway inhibitor, was US Food and Drug
Administration (FDA) approved for advanced basal cell carcinomas (BCCs) based on a single, nonrandomized,
phase-II trial. Consequently, additional clinical data are critical to confirm the efficacy and safety of vismodegib.Objective: We sought to assess efficacy and safety of vismodegib, while providing early drug access to
patients with advanced BCC and limited treatment options.Methods: This was an open-label, multicenter study in patients with advanced BCC inappropriate
for radiotherapy or surgery. Patients received 150mg vismodegib daily until disease progression or intolerable
toxicity. Tumor response was assessed via Response Evaluation Criteria in Solid Tumors version 1.0.Results: A total of 119 patients with advanced BCC took vismodegib for a median of 5.5 months. Objective
responses occurred in 46.4% of locally advanced BCC and 30.8% of patients with metastatic BCC. Response
was negatively associated with prior systemic therapy in patients with locally advanced BCC (P = .002).
Mean follow-up for safety was 6.5 months, with muscle spasms (70.6%), dysgeusia (70.6%), alopecia
(58.0%), and diarrhea (25.2%) as the most common adverse events.Limitations: Abbreviated follow-up time because of study termination upon FDA approval was a limitation.Conclusion: This study provides important clinical data supporting the efficacy and safety of vismodegib.
Larger studies are underway to assess predictors of response and long-term outcomes. ( J Am Acad
Dermatol 2014;70:60-9.)
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Chang et al 61Basal cell carcinoma (BCC) is the most common
human malignancy, with an estimated 1.6 million
new patients treated in the United States in 2006.1-3
Most BCCs are effectively cured, but in some
cases may progress to advanced BCC (refers to
both locally advanced and distantly metastatic
BCCs).4-6 Locally advanced BCCs can be debilitatingCAPSULE SUMMARY
d Vismodegib was approved by the US
Food and Drug Administration for
advanced basal cell carcinoma after a
single phase-II clinical trial.
d To our knowledge, this is the largest
completed trial to date on vismodegib,
with 119 patients with this rare condition.
d This study confirms prior safety and
efficacy and explores clinical factors
associated with tumor response.and lead to significant mor-
bidity.4,7,8 Surgery or radio-
therapy may be untenable
choices9,10 because of poten-
tial loss of vital function
with these treatments.7,11,12
In metastatic BCC, a rare but
often fatal condition, distant
metastases may preclude
surgery or radiation.6,13,14
Conventional chemother-
apy such as cisplatin has
been reported to improve tu-
mor response, but improve-
ments in progression-free
survival or overall survival
have not been demonstrated.15 Chemotherapy has
also been examined as an adjuvant to radiation but
this has not demonstrated improved survival either.16
Hence, effective treatment for advanced BCCs
represented a significant unmet medical need.
Smoothened (SMO) inhibitors are highly
targeted therapies based on the biology of BCCs.
Aberrant Hedgehog pathway signaling, driven
by genetic loss of function alterations in Patched
or activating mutations in SMO,17,18 is critical
in BCC pathogenesis.10,19,20 Loss of Patched contrib-
utes to approximately 90% of sporadic BCCs,
whereas SMO-activating mutations occur in approx-
imately 10% of sporadic BCCs.21-23 Hence, Hedgehog
pathway inhibitors represent a novel therapeutic op-
tion for BCC treatment.19,24
Vismodegib is the first US Food and Drug
Administration (FDA)-approved oral, small-molecule,
Hedgehog pathway inhibitor effective in advanced
BCC.5,9,14,24,25 In a phase-II BCC study (ERIVANCE),
104 patients with advanced BCC received vismodegib,
with a 43% response in locally advanced BCC and a
30% response in metastatic BCC groups.14 Because of
significant unmet medical need in patients with
advanced BCC, vismodegib received priority FDA
approval after this phase-II clinical trial.26,27
Despite FDA approval, additional clinical data in a
greater number of patients with advanced BCC
are critical to confirm the safety and efficacy of
vismodegib. This study provided an opportunity for
patients with advanced BCC and limited treatment
options to receive early drug access. Furthermore,this study is the largest peer-reviewed, published
study to date on vismodegib in patients with ad-
vanced BCC, allowing exploratory analysis of factors
that predict advanced BCC response to vismodegib.
METHODS
Study patientsAfter approval from
institutional review boards,
and in accordance with
Declaration of Helsinki
guidelines, all patients pro-
vided written informed
consent for trial participa-
tion. This study was regis-
tered as NCT01160250 on
Clinicaltrials.gov.
Inclusion criteria
Eligible patients were
18 years or older; had ade-
quate organ function; had
an Eastern CooperativeOncology Group (ECOG) performance status of 2 or
less; and had measurable, evaluable disease as
defined by Response Evaluation Criteria in Solid
Tumors (RECIST) version 1.0 criteria.28 BCC
metastatic to the bone, termed ‘‘nonmeasurable’’ dis-
ease by RECIST version 1.0 was included. Patients
with locally advancedBCC had at least 1 histologically
confirmed lesion 10 mm or larger in diameter with
written confirmation from a surgical specialist that
the tumor was inoperable, or that surgery was
contraindicated. Surgery was considered inappropri-
ate if BCC recurred in the same location after 2 or
more surgical procedures and curative resection was
deemed unlikely, or when there was substantial
morbidity and/or deformity anticipated. Patients
with locally advanced BCC were required to have
had prior radiation therapy to greater than or equal
to 1 target lesion unless contraindicated or inappro-
priate. Histologic confirmation of locally advanced
BCC and metastatic BCC lesion(s) was required in all
cases. Patients with basal cell nevus syndrome
(BCNS) could enroll if they met inclusion criteria.
Women of childbearing potential and men with
female partners of childbearing potential were re-
quired to use medically reliable contraception be-
cause of vismodegib teratogenicity.
Exclusion criteria
Patients were ineligible to participate if they had
major organ dysfunction; were pregnant, lactating,
or unwilling to practice birth control; had completed
antitumor therapy less than 21 days before treatment
Abbreviations used:
AE: adverse event
BCC: basal cell carcinoma
BCNS: basal cell nevus syndrome
ECOG: Eastern Cooperative Oncology Group
FDA: US Food and Drug Administration
ORR: objective response rate
RECIST: Response Evaluation Criteria in Solid
Tumors
SMO: Smoothened
TEAE: treatment-emergent adverse event
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uncontrolled medical illnesses that would contrain-
dicate vismodegib; were on concurrent antitumor
therapy; or had a less than 12-week life expectancy.
Study design
This was an open-label, 2-cohort, multicenter
study. All patients received 150 mg oral vismodegib
once daily, with treatment cycles defined as every 28
days. Clinic visits occurred every 1 to 2 treatment
cycles. The clinic visits included medical history;
adverse event (AE) recording; ascertainment of con-
comitant medications; ECOG performance status;
vital signs including weight; physical examination;
complete blood cell count and metabolic panel;
and urinalysis. Screening electrocardiography was
also performed. Treatment was administered
until investigator-assessed disease progression,
unmanageable toxicities, patient or physician
request to discontinue, or study termination by
sponsor. Dose reduction was not permitted. Dose
interruption up to 8 weeks was permitted to manage
toxicity.
Safety analysis/assessment
The safety-evaluable population included
patients receiving greater than or equal to 1 vismo-
degib dose. Safety was assessed by AE collection
including incidence, type, severity, vismodegib
discontinuation/interruption because of AEs, and
on-study deaths (drug and nondrug related).
Descriptions of all collected AEs were mapped to
Medical Dictionary of Regulatory Activities terms
(version 15.0) and graded using the National Cancer
Institute Common Terminology Criteria for Adverse
Events (version 4.0) (http://evs.nci.nih.gov/ftp1/
CTCAE/CTCAE_4.03_2010-06-14_QuickReference_
8.5x11.pdf).
Efficacy analysis/assessment
Patients receiving greater than or equal to 1 dose
of vismodegib and having greater than or equal to
1 follow-up tumor assessment (or who died within30 days of first dose of vismodegib) were included in
the efficacy-evaluable population. Tumor responses
were investigator-assessed according to RECIST
version 1.0 criteria. Physical examinations were
performed to assess measurable tumors within 7
days of treatment initiation, then every 4 to 8 weeks.
Patients with radiographically measurable disease
underwent computed tomography or magnetic
resonance imaging assessment within 30 days before
treatment initiation, then every 8 to 16 weeks
thereafter. Patients with nonmeasurable disease, eg,
bone metastases, were evaluated for disease
progression by the clinical judgment of the treating
physician. Objective tumor responses, defined as the
best overall complete response or partial response,
were confirmed by investigators using 2 consecutive
tumor assessments performed at least 4 weeks apart
according to RECIST version 1.0. For instance, if a
tumor had a partial response followed by complete
response but no second assessment of complete
response, the tumor was labeled as partial response.
For this study, appearance of a new cutaneous BCC
was considered progressive disease if the lesion was
larger than 5 mm and clearly documented as not
previously present.Statistical analysis
Patient data were collected through 30 days after
the last vismodegib dose for the last patient enrolled.
Efficacy and safety data were summarized by
descriptive statistics. The association between tumor
response and selected baseline characteristics of age,
prior radiotherapy exposure, prior systemic cancer
therapy, and number of involved sites was evaluated
using Fisher exact test.RESULTS
Patient demographics and baseline
characteristics
In all, 120 patients (locally advanced BCC n = 62,
metastatic BCC n = 58) enrolled at 11 US sites. Of
these, 119 patients (locally advanced BCC n = 62,
metastatic BCC n = 57) were safety-evaluable and 95
(locally advanced BCC n = 56, metastatic BCC n = 39)
were efficacy-evaluable (Fig 1). Demographic and
baseline characteristics were similar for both locally
advanced BCC and metastatic BCC cohorts (Table I).
RECIST-measurable disease at baseline comprised
87.4% of patients enrolled. The remaining 12.6% of
patients had biopsy-proven metastatic BCC to bone,
classified as nonmeasurable disease by RECIST
version 1.0, but evaluable on imaging. Seven patients
with BCNS had biopsy-proven distantly metastatic
BCC.
Patients enrolled n = 120* (100%)
Safety
n = 119
Efficacy
n = 95
Non-evaluable for safety n = 1 (0.8%)
  • No study drug administered n = 1 (0.8%)†
Safety-evaluable population§ n = 119 (99.2%)
  • Locally advanced (laBCC) n = 62 (51.7%)
  • Metastatic (mBCC) n = 57 (47.5%)
Non-evaluable for efficacy n = 25 (20.8%)
  • No study drug administered n = 1 (0.8%)‡
  • No measurable disease at baseline n = 15
    (12.5%)‡
‡
  • No post-baseline tumor assessment and 
    no on-study death n = 25 (20.8%)
Efficacy-evaluable population¶ n = 95 (79.2%)
  • Locally advanced (laBCC) n = 56 (46.7%)
  • Metastatic (mBCC) n = 39 (32.5%)
Fig 1. CONSORT schematic on patient enrollment. Percentages were based on patients
enrolled (n = 120). *One patient was inadvertently assigned a new patient identification
number after rejoining the study, 5 months after being lost to follow-up. All results for this
patient were presented under the original patient identification number. yOne patient was not
included in the safety-evaluable population because the patient started the first cycle of
treatment and then was lost to follow-up. As the drug bottle or drug diary was not returned to
the site, it could not be confirmed how many (if any) doses had been taken. zPatients could be
counted in more than 1 of the efficacy-nonevaluable reasons. xDefined as enrolled patients
who had received at least 1 dose of vismodegib. {Defined as patients who had received at least
1 dose of vismodegib, had measurable disease at baseline, and had at least 1 follow-up tumor
assessment or died within 30 days from the last dose of study drug. laBCC, Locally advanced
BCC; mBCC, metastatic BCC.
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Treatment exposure and study
termination. The median duration of vismodegib
treatment was 5.5 (range 0.4-19.6) months. The
mean received dose was approximately 95% of
planned. The median safety follow-up was 6.5
(range 1.4-20.6) months. The relatively short median
duration of vismodegib treatment was reflective
of FDA approval, at which point the sponsor
terminated the study and patients were transitioned
to commercially available vismodegib. The sponsor
study termination was the primary reason for
discontinuation. Of the 120 patients enrolled, 79
(locally advanced BCC n = 44, metastatic BCC n = 35)
were transitioned to commercial drug. Other
reasons for study discontinuation included disease
progression (n = 16), subject decision (n = 7), loss to
follow-up (n = 6), and AEs (n = 5).
Adverse events. Almost all safety-evaluable
patients (n = 116; 97.5%) experienced a treatment-
emergent AE (TEAE). These were typically grades
1 and 2, with few patients experiencing AEs of grade
3 (n = 24), grade 4 (n = 9), and grade 5 (death; n = 2).
Common ($ 15% incidence) TEAEs are listed in
Table II. Themedian time to onset of common TEAEs
was generally less than 60 days after treatmentinitiation; however, alopecia and decreased weight
had longer onset times (median 87 and 175 days,
respectively). Most TEAEs (eg, muscle spasm,
dysgeusia, alopecia) occurred within the first 7
treatment cycles (Fig 2). Among women of
childbearing potential (n = 8), 4 developed
amenorrhea or irregular menses; 1 patient had
amenorrhea for longer than 6 months (grade 3),
1 patient for more than 3 to 6 months (grade 2), and 2
patients for 1 to 3 months (grade 1). All amenorrhea
AEs were ongoing at study termination.
Serious AEs, TEAE-related withdrawal, and
study deaths. Eighteen patients (locally advanced
BCC n = 9, metastatic BCC n = 9) reported serious AEs
that were grade 3 (n = 12), grade 4 (n = 6), or grade 5
(n = 2). Muscle spasm (n = 1, grade 3) was the only
vismodegib-related serious AE reported. Seven
patients discontinued vismodegib because of AEs
(2 were drug related and 5 unrelated). In the
locally advanced BCC cohort, TEAEs leading to
discontinuation included 1 patient each with wound
complication, muscle spasm, worsening/recurrence
of pre-existing conditions such as B-cell lymphoma,
mesothelioma, and squamous cell carcinoma. In the
metastatic BCC cohort, AEs leading to treatment
discontinuation included 1 patient with fatigue and
Table I. Patient demographics and baseline disease characteristics in the safety-evaluable population
Demographic All patients (n = 119) laBCC (n = 62) mBCC (n = 57)
Median age, y (range) 62.0 (24-100) 61.0 (26-92) 63.0 (24-100)
Male, n (%)* 88 (73.9) 43 (69.4) 45 (78.9)
White, n (%) 116 (97.5) 60 (96.8) 56 (98.2)
ECOG performance status, n (%)
0 69 (58.0) 39 (62.9) 30 (52.6)
1 41 (34.5) 19 (30.6) 22 (38.6)
2 9 (7.6) 4 (6.5) 5 (8.8)
Patients with basal cell nevus syndrome, n (%) 19 (16.0) 12 (19.4) 7 (12.3)
BCC history
Mean time from initial diagnosis of BCC to study treatment, y (6SD) 8.6 (12.5) 12.1 (15.0) 4.9 (7.7)
Patients with measurable disease at baseline, n (%) 104 (87.4) 56 (90.3) 48 (84.2)
Patients with laBCC, n (%) 62 (52.1) 62 (100) —
Inoperable — 27 (43.5) —
Surgery medically contraindicated, n (%) — 35 (56.5) —
Recurrent BCC unlikely to be curatively resected — 10 (16.1) —
Anticipated substantial morbidity and/or deformity from surgery — 28 (45.2) —
Other contraindications to surgery — 2 (3.2) —
No. of laBCC and/or mBCC sites involved, n (%)
# 3 — 56 (90.3) 49 (86.0)
[3 — 6 (9.7) 8 (14.0)
Site of disease, n (%)
Lung — — 30 (52.6)
Skin — 61 (98.4) 29 (50.9)
Face — 40 (64.5) 5 (8.8)
Scalp — 24 (38.7) 6 (10.5)
Neck — 14 (22.6) 12 (21.1)
Trunk — 11 (17.7) 6 (10.5)
Arm — 7 (11.3) 3 (5.3)
Leg — 4 (6.5) —
Other skin site — 12 (19.4) 16 (28.1)
Lymph node — — 16 (28.1)
Bone — — 16 (28.1)
Liver — — 4 (7.0)
Other site — 4 (6.5)y 12 (21.1)z
Previous treatments, n (%)
Surgery 111 (93.3) 57 (91.9) 54 (94.7)
Radiotherapy 55 (46.2) 20 (32.3) 35 (61.4)
Systemic therapy 31 (26.1) 11 (17.7) 20 (35.1)
BCC, Basal cell carcinoma; ECOG, Eastern Cooperative Oncology Group; laBCC, locally advanced BCC; mBCC, metastatic BCC.
*Percentages are based on n value in top row.
yOther sites for laBCC included medial canthus, right eye, dura, shoulder, and orbit.
zOther sites included left axilla and clavicle, brain, chest, sacrum, periorbital, kidney, ocular, left axilla, right axilla, T10-T12, lumbar spine, and
left gingivobuccal sulcus oral cavity.
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rates were not significantly different between locally
advanced BCC and metastatic BCC cohorts.
In this study, death because of disease progres-
sion was not considered a grade-5 AE. Three patients
died on study (metastatic BCC, n = 2; locally
advanced BCC, n = 1), defined as during or within
30 days of receiving the last treatment dose. Reported
causes in the locally advanced BCC cohort included
recurrence of a previously treated squamous cell
carcinoma and wound complication. The cause ofdeath of the patient in the metastatic BCC cohort
was disease progression. None of the deaths were
considered by the investigator to be treatment
related.
Efficacy
Objective response and best overall
response rate. In efficacy-evaluable patients
(locally advanced BCC n = 56, metastatic BCC
n = 39), objective responses achieved by patients
with locally advanced BCC and metastatic BCC were
Table II. Common ($ 15% incidence) treatment-emergent adverse events with vismodegib in the safety-
evaluable population
Common AE
($ 15% incidence)
Median time to AE onset,
d (95% CI)
All AEs,
n (%)
Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%)
Grade 4,
n (%)
Grade 5,
n (%)
Muscle spasm 37 (28-44) 84 (70.6) 63 (52.9) 19 (16.0) 2 (1.7) 0 0
Dysgeusia 41 (30-52) 84 (70.6) 68 (57.1) 16 (13.4) 0 0 0
Alopecia 87 (74-104) 69 (58.0) 57 (47.9) 12 (10.1) 0 0 0
Diarrhea 38 (22-116) 30 (25.2) 23 (19.3) 5 (4.2) 1 (0.8) 1 (0.8) 0
Nausea 30 (11-130) 23 (19.3) 19 (16.0) 4 (3.4) 0 0 0
Fatigue 42 (16-120) 23 (19.3) 14 (11.8) 8 (6.7) 1 (0.8) 0 0
Weight decrease 175 (114-293) 19 (16.0) 12 (10.1) 7 (5.9) 0 0 0
AE, Adverse event; CI, confidence interval (95% distribution-free confidence limits for percentiles).
Percentages were based on safety-evaluable patients (n = 119).
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Fig 2. Cumulative occurrence of adverse events (AEs) by cycle. AEs with earlier onset included
muscle spasm and dysgeusia. AEs with later onset included alopecia and weight loss.
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Chang et al 6546.4% and 30.8%, respectively (Fig 3). Eight patients
(8.4% of all study patients) achieved complete
response (locally advanced BCC n = 6, metastatic
BCC n = 2), whereas 30 patients (31.6% of all
study patients) achieved partial response (locally
advanced BCC n = 20, metastatic BCC n = 10). In all,
47 patients (49.5% of all study patients) experienced
stable disease (locally advanced BCC n = 27,
metastatic BCC n = 20). In total, 94.6% patients in
the locally advanced BCC cohort and 82.1% patients
in the metastatic BCC cohort had complete response,
partial response, or stable disease. No patient with
locally advanced BCC had progressive disease,
whereas 3 patients with metastatic BCC exhibited
progressive disease (Table III).
Objective response rate (ORR)
associations. Exploratory analysis of demographic
or clinical factors that associate with ORR was
performed. Because of sample size limitation, the
associations selectedwere limited to age, use of prior
radiotherapy, use of prior systemic chemotherapy,
and the number of concurrent sites involved withBCC (Table IV). ORR was not significantly associated
with age, number of sites involved, or use of prior
radiotherapy in either the locally advanced BCC or
the metastatic BCC cohorts. However, the ORR for
patients with locally advanced BCC was significantly
different in those with versus without previous
systemic chemotherapy (0% and 55%, respectively;
P = .002). All patients with locally advanced BCC
who received prior systemic therapy experienced
stable disease as best overall response. Duration of
treatment was similar for patients with locally
advanced BCC with or without prior systemic
treatment (5.7 vs 6.4 months). Prior systemic
therapies reported by the treating investigators
included: vismodegib (n = 4), IPI-926, another
Hedgehog pathway inhibitor, dasatinib, rofecoxib,
photodynamic therapy, and cisplatin plus peme-
trexed (n = 1 each) for an underlying mesothelioma,
with target BCC concurrently exposed to this treat-
ment. With removal of rofecoxib and photodynamic
therapy as systemic therapy for BCCs, the negative
association was still significant (P = .01). Sample size
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Fig 3. Maximum postbaseline percentage decrease in the sum of the longest diameters (SLD)
of measurable lesions in patients. Data for patients with locally advanced (A) and metastatic
(B) basal cell carcinoma. Each column represents an individual patient.
Table III. Best overall response (Response
Evaluation Criteria in Solid Tumors26) to vismodegib
treatment at study termination
Responses
laBCC
(n = 56)
mBCC
(n = 39)
Objective response, n (%)*
[95% CI]
26 (46.4)
[33.0-60.3]
12 (30.8)
[17.0-47.6]
Complete response, n (%) 6 (10.7) 2 (5.1)
Partial response, n (%) 20 (35.7) 10 (25.6)
Stable disease, n (%) 27 (48.2) 20 (51.3)
Progressive disease, n (%) 0 3 (7.7)
Unevaluable/missing, n (%) 3 (5.4) 4 (10.3)
Median (range) time to
objective response, moy
2.6 (1.0-11.0) 2.6 (1.4-12.6)
CI, Confidence interval (based on the Clopper-Pearson method);
laBCC, locally advanced BCC; mBCC, metastatic BCC.
*Percentages were based on n in the top row.
yResponse assessments every 4-8 wk by physical examination and
every 8-16 wk by radiographic examination.
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therapy did not lead to a significantly different ORR
in the metastatic BCC cohort.*Note: Additional description of the scalp BCC has been published
in JAMA Dermatology (Vignette section) 2013;149:639-41.
Current photographs are not previously published.Illustrative patient case studies
Case study 1: Differential shrinkage in locally
advanced BCCs after retreatment with vismodegib.
An 84-year-old man with a long history of locally
advanced BCCs enrolled in the current expandedaccess study after a 9-month course of vismodegib
(150 mg daily) through the phase-II clinical trial
(ERIVANCE BCC). Left scalp and preauricular locally
advanced BCCs achieved partial response and he
discontinued from ERIVANCE 7 months earlier for
personal reasons. In the current study, target lesions
on the left ear and left chin demonstrated a partial
response, and the nontarget left scalp and preauric-
ular locally advanced BCCs demonstrated complete
response and visible tumor shrinkage (Fig 4, A),
respectively, after 8 months of retreatment. Hence,
retreatment can be beneficial but responses to
vismodegib in different BCCs within an individual
can vary.
Case study 2*: Periocular BCCs in a patient with
BCNS shows complete response. A 55-year-old man
with BCNS presented with multiple locally advanced
BCCs* including 2 periocular BCCseright medial
canthus and left lateral canthus (Fig 4, B I)eand a
13-cm BCC on the right scalp eroding calvarium. The
patient received 150 mg vismodegib once daily. His
periocular lesions responded with complete regres-
sion. He continued on vismodegib after study termi-
nation and the periocular lesions have remained
clear without evidence of disease at 24 months
Table IV. Association of baseline variables and objective response by univariate analysis
Outcome laBCC cohort (n = 56) mBCC cohort (n = 39)
Age, y \65 $ 65 P value \65 $ 65 P value
n 32 24 1.000 21 18 1.000
Objective response, n (%) 15 (47) 11 (46) 6 (29) 6 (33)
Median treatment duration, mo 5.3 7.7 6.2 5.2
Prior radiotherapy Yes No P value Yes No P value
n 15 41 .561 23 16 .174
Objective response, n (%) 8 (53) 18 (44) 5 (22) 7 (44)
Median treatment duration, mo 6.9 5.4 5.5 7.2
Prior systemic therapy Yes No P value Yes No P value
n 9 47 .002 13 26 .714
Objective response, n (%) 0 (0) 26 (55) 3 (23) 9 (35)
Median treatment duration, mo 5.7 6.4 5.1 6.3
No. of sites involved (laBCC and/or
mBCC) 1 Site [1 Sites P value 1 Site [1 Sites P value
n 30 26 .295 16 23 1.000
Objective response, n (%) 16 (53) 10 (38) 5 (31) 7 (30)
Median treatment duration, mo 7.0 5.0 5.8 5.7
laBCC, Locally advanced BCC; mBCC, metastatic BCC.
Percentages were based on N in each subgroup cohort. P values (uncorrected) were derived from Fisher exact test.
Objective response was significantly associated with the number of prior systemic treatments.
Prior systemic treatments were: Smoothened inhibitor drugs (including drugs besides vismodegib) and nontargeted chemotherapy.
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responded and the residual BCC was excised with
negative margins. This case illustrates the use of
vismodegib in periocular lesions where surgery may
risk vision loss.
DISCUSSION
To our knowledge, this is the largest peer-
reviewed, published study to date of vismodegib in
advanced BCCs. In light of priority review and
approval of vismodegib by the FDA based on a single
phase-II study,14 this study contributes important
additional data confirming the safety and efficacy of
vismodegib for advanced BCCs. The observed safety
profile based on incidence and severity of AEs is
comparable with the phase-II study with no new
safety signals observed. Longer follow-up times will
be critical to assess long-term outcomes and
the safety profile of vismodegib treatment. The
international vismodegib safety study, STEVIE
(NCT01367665), which aims to enroll 1200 patients,
will likely address these important questions.
This clinical study (with ORR 46% in patients
with locally advanced BCC and 31% in
patients with metastatic BCC) shows similar
overall clinical activity to the phase-II BCC study
(with ORR 43% in patients with locally advanced
BCC and 30% in those with metastatic BCC). This is
despite several differences in response assessmentbetween the 2 studies. First, this expanded access
study used RECIST criteria for both cohorts and did
not use independent review to assess the tumor
responses to vismodegib. Second, a few patients
(6 of 119) in this study had been exposed to an SMO
inhibitor before enrollment, which was not the case
in the phase-II study.
Data on clinical factors that predict ORR, as
explored in this study, will be useful for clinicians
to identify patients with advanced BCCmost likely to
benefit from vismodegib. Although this study has a
relatively small sample size for ORR predictions, a
prospective, observational, US disease registry
(RegiSONIC; NCT01604252) is currently underway
to assess effects of different treatments in advanced
BCC and may provide additional data about
predictors of tumor response.
In conclusion, this study provides important
additional clinical data supporting vismodegib as a
useful treatment for advanced BCCs. Given the
complexity of many of these patients, and the recent
availability of vismodegib for commercial use,
multidisciplinary efforts among dermatologists,
medical oncologists, radiation oncologists, otolaryn-
gologists, and surgical oncologists may be needed to
optimize patient outcomes.
The authors would like to thank all the patients and
their families for participating in this study. The authors
would also like to thank the following investigators for
Fig 4. Case studies of patients with advanced basal cell carcinoma (BCC). A, Retreatment with
vismodegib demonstrating a mixed response, with left preauricular showing stable disease
followed by progressive disease even though a separate scalp lesion showed complete
response. B, A patient with basal cell nevus syndrome and periocular locally advanced BCCs in
the right medial canthus and left lateral canthus with durable complete response after study
end, as followed up in dermatology clinic 20 months after vismodegib initiation. All
photographs are presented in this article with the consent of the patients obtained by the
authors.
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Friedlander, Joel Gelfand, Omid Hamid, Patricia LoRusso,
Thomas Olencki, Anthony Oro, Aleksandar Sekulic, and
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